Baker Bros. Advisors’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Baker Bros. Advisors’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-69,966	Closed	-$8.85M	–	126
2022 Q2	$8.85M	Hold	69,966	–	–	0.05%	64
2022 Q1	$8.87M	Hold	69,966	–	–	0.05%	69
2021 Q4	$9.17M	Hold	69,966	–	–	0.04%	80
2021 Q3	$8.56M	Hold	69,966	–	–	0.04%	80
2021 Q2	$7.97M	Hold	69,966	–	–	0.04%	83
2021 Q1	$8.41M	Hold	69,966	–	–	0.04%	82
2020 Q4	$7.11M	Sell	69,966 -7,810	-10%	-$724K	0.03%	84
2020 Q3	$6.01M	Sell	77,776 -4,200	-5%	-$358K	0.02%	77
2020 Q2	$9.14M	Buy	81,976 +40,000	+95%	+$3.48M	0.04%	63
2020 Q1	$3.02M	Buy	+41,976	New	+$3.59M	0.02%	80

Other funds holding KRTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Baker Bros. Advisors's KRTX Position: Q3 2022 in Review

Baker Bros. Advisors sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q3 2022, closing a stake of 69,966 shares — an estimated $8.85M sold.

Baker Bros. Advisors first reported a position in KRTX in Q1 2020 and held it in 10 quarters. The position peaked at $9.17M in Q4 2021. 257 funds tracked by Wall St. Rank hold KRTX as of Q3 2022.

Baker Bros. Advisors reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Baker Bros. Advisors sold 69,966 Karuna Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $8.85M.
Baker Bros. Advisors first reported a position in Karuna Therapeutics, Inc. Common Stock in Q1 2020 and held it in 10 quarters.
Baker Bros. Advisors's Karuna Therapeutics, Inc. Common Stock position peaked at $9.17M in Q4 2021.
257 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Baker Bros. Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.